Cell Mogrify

Activities: Pharmaceutical

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  2. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
  3. LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
  4. Memel Biotech and Therabest collaborate to develop exosome-based cell therapies The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
  5. Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

Related Content

Mogrify appoints Dr Jane Osbourn as Chair of the Board

The OBE is also Chair of the Board of Directors of the BioIndustry Association, a Director of Babraham Bioscience Technologies, a Director of Cambridge Enterprise
Pharmaceutical

Mogrify appoints new CBO and COO

New executives at the biopharma company will be Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer
Research & Development

Cell Mogrify receives funding for regenerative cell therapy research

The funding from Innovate UK is designated to accelerate regenerative cell therapies, focusing on data-driven cell conversions
Recruitment

Cell Mogrify undergoes period of change

A cash injection and change in leadership gives momentum to the cell therapy company for direct cellular conversion platform
Subscribe now